Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
01:00am, Wednesday, 03'rd Jun 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following s
argenx to Host Myositis R&D Webinar on June 23, 2026
01:00am, Thursday, 28'th May 2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an
argenx to Present at Upcoming Investor Conferences
01:00am, Wednesday, 27'th May 2026
May 27, 2026Amsterdam, the Netherlands - argenx (Euronext and Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann
argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System
08:30am, Friday, 22'nd May 2026
argenx (ARGX) is building a differentiated autoimmune platform, leveraging VYVGART's commercial success into a self-reinforcing growth engine. ARGX delivered 63% YoY sales growth in Q1 2026, maintains
The Biology Came First.
09:00am, Monday, 18'th May 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:40pm, Tuesday, 12'th May 2026
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease
01:37pm, Monday, 11'th May 2026
Argenx SE – ADR (NASDAQ:ARGX) shares are up during Monday's session as the company celebrates a recent FDA approval for its drug, VYVGART, which adult patients with generalized myasthenia gravis can
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
05:20pm, Friday, 08'th May 2026
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
05:11pm, Thursday, 07'th May 2026
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
argenx to Present at BofA Securities 2026 Health Care Conference
04:30pm, Wednesday, 06'th May 2026
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
04:01pm, Wednesday, 06'th May 2026
Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of p
HRMY or ARGX: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 04'th May 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
01:00am, Thursday, 30'th Apr 2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
Mirae Asset Global Investments Co. Ltd. Buys 2,018 Shares of argenex SE $ARGX
05:16am, Monday, 20'th Apr 2026
Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of argenex SE (NASDAQ: ARGX) by 22.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC.
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
01:00am, Saturday, 18'th Apr 2026
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, O
